$DMPI News Article - DelMar Pharmaceuticals Achieves Two-Thirds Enrollment for Phase 2 Clinical Trial of VAL-083 As First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma MultiForme (GBM)
https://marketwirenews.com/news-releases/delm...06410.html